Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Bought by Advisors Asset Management Inc.

Advisors Asset Management Inc. lifted its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 29.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 12,661 shares of the biotechnology company’s stock after acquiring an additional 2,897 shares during the period. Advisors Asset Management Inc.’s holdings in Corcept Therapeutics were worth $586,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in Corcept Therapeutics during the 3rd quarter valued at approximately $25,000. Kathleen S. Wright Associates Inc. acquired a new position in Corcept Therapeutics during the 3rd quarter valued at approximately $36,000. Park Place Capital Corp acquired a new position in Corcept Therapeutics during the 2nd quarter valued at approximately $32,000. Atwood & Palmer Inc. acquired a new position in Corcept Therapeutics during the 2nd quarter valued at approximately $35,000. Finally, GAMMA Investing LLC boosted its position in Corcept Therapeutics by 85.4% during the 3rd quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 1,147 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Transactions at Corcept Therapeutics

In other news, insider Joseph Douglas Lyon sold 1,411 shares of Corcept Therapeutics stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $56.72, for a total transaction of $80,031.92. Following the transaction, the insider now owns 8,494 shares in the company, valued at approximately $481,779.68. The trade was a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Gary Charles Robb sold 11,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the completion of the transaction, the insider now owns 22,772 shares in the company, valued at $1,053,888.16. This trade represents a 32.57 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,611 shares of company stock valued at $1,563,548. Corporate insiders own 20.50% of the company’s stock.

Corcept Therapeutics Stock Up 0.0 %

CORT opened at $58.60 on Thursday. Corcept Therapeutics Incorporated has a one year low of $20.84 and a one year high of $61.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The stock’s fifty day moving average is $49.20 and its 200-day moving average is $38.52. The company has a market capitalization of $6.14 billion, a PE ratio of 46.49 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $182.55 million for the quarter, compared to the consensus estimate of $171.97 million. During the same quarter in the previous year, the business earned $0.28 EPS. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. On average, equities analysts predict that Corcept Therapeutics Incorporated will post 1.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CORT shares. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Piper Sandler boosted their price objective on Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, September 18th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Truist Financial lifted their target price on Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research note on Monday, September 30th. Finally, StockNews.com downgraded Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $65.25.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.